TLR Signaling Pathways: Opportunities for Activation and Blockade in Pursuit of Therapy

Author(s): K. Hoebe, Z. Jiang, P. Georgel, K. Tabeta, E. Janssen, X. Du, B. Beutler

Journal Name: Current Pharmaceutical Design

Volume 12 , Issue 32 , 2006

Become EABM
Become Reviewer
Call for Editor


The identification of the TLRs as key sensors of microbial infection has presented a series of new targets for drug development. The TLRs are linked to the most powerful inflammatory pathways in mammals. The question arises from the start: do we wish to stimulate TLR signaling in order to eradicate specific infections and/or neoplastic diseases? Or do we wish to block TLR signaling to treat inflammatory diseases? If we accept that it would be useful to modulate TLR signaling, the next step is to identify the correct molecular target(s) for the task. Perhaps it might even be possible to exercise selectivity, modulating some aspects of TLR signaling and not others. Classical and reverse genetic analyses offer insight into the possibilities that exist, and point to specific checkpoints within signaling pathways at which modulation might normally be imposed.

Keywords: TNF neutralization, sterile inflammation, microbial adjuvants, MyD88-dependent signal transduction, Trif mutation

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2006
Page: [4123 - 4134]
Pages: 12
DOI: 10.2174/138161206778743466
Price: $65

Article Metrics

PDF: 11